Cumberland Pharmaceuticals Inc.
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from Cumberland Pharmaceuticals Inc.'s yearly results (2022–2025), compared with Healthcare companies in United States. Tap ? on any ratio for what it means.
What stands out
- Self-Funding Ratio: Over the last 3 years its own operating cash covered its investment spending (capex) 12.8 times. Higher than 96% of Healthcare companies in United States.
- Debt Due Cover Ratio: Debt due within a year is covered 10.5 times by its yearly operating cash. Higher than 85% of Healthcare companies in United States.
Where $100 of sales goes
Latest year (Dec 2025). Taxes and other income are not shown, so the parts need not add up to 100.
Cash quality
Profit Cash Ratio
—Loss-making or profit too small
Over the last 3 years profit was a loss or under 2% of sales, so cash per 100 of profit is not meaningful.
Self-Funding Ratio
12.8×Over the last 3 years its own operating cash covered its investment spending (capex) 12.8 times.
Higher than 96% of Healthcare companies in United States.
Cash Locked Ratio
$10For every $100 of sales, $10 is tied up in day-to-day operations (money owed by customers + stock − money owed to suppliers), against $29 tied up three years earlier.
Less money tied up than 80% of Healthcare companies in United States.
Growth quality
Steadiness Ratio
1/3 · 1/3Sales grew in 1 of the last 3 years; profit grew in 1 of 3.
Less steady than 70% of Healthcare companies in United States.
Growth Efficiency Ratio
$109Sales grew 6% in 3 years; of every extra $100 of sales, $109 became extra profit.
Higher than 82% of Healthcare companies in United States.
Asset Productivity Ratio
+6% / -17%In 3 years sales changed by +6% while total assets changed by -17%. Sales grew faster than assets.
Balance-sheet strength
Debt Due Cover Ratio
10.5×Debt due within a year is covered 10.5 times by its yearly operating cash.
Higher than 85% of Healthcare companies in United States.
Cash Cushion Ratio
+1%Cash, after subtracting all debt, equals 1% of its market value (net cash).
Lower than 66% of Healthcare companies in United States.
Tangible Assets Ratio
81%Of every $100 the company owns, $81 is in tangible assets such as plants, cash, stock and receivables; the rest is goodwill and other intangibles.
More tangible than 50% of Healthcare companies in United States.
Tangible Net Worth Ratio
40%Of every $100 of net worth, $40 is tangible; the rest is goodwill and other intangibles, often from buying other companies.
Less tangible than 58% of Healthcare companies in United States.
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (13)
Cumberland Pharmaceuticals Inc. made a loss over the last year. Cumberland Pharmaceuticals Inc. owes $0.73 for every $1 it owns. Cumberland Pharmaceuticals Inc. made a loss in each of the last two years.
Compared with Healthcare companies in United States · latest annual results Dec 2025.
P/E ratio
LossCumberland Pharmaceuticals Inc. made a loss over the last year, so its P/E ratio is not meaningful.
P/B ratio
7.29The share price is 7.29 times Cumberland Pharmaceuticals Inc.'s book value per share, higher than 81% of Healthcare companies in United States.
Market cap
$127 MThe total market value of all of Cumberland Pharmaceuticals Inc.'s shares at today's price (share price × number of shares), smaller than 63% of Healthcare companies in United States. PosiCap size class: Mini Cap.
Net worth (book value)
$17 MWhat Cumberland Pharmaceuticals Inc. would have left on paper if it sold everything it owns and paid everything it owes, from its latest balance sheet (30 Jun 2026).
Book value per share
$1.16Net worth divided by the number of shares. The share price of $8.48 is 7.3 times this, which is the P/B above.
Return on equity (ROE)
-14.4%Cumberland Pharmaceuticals Inc. lost 14.4% of its shareholders' money over the last year, higher than 68% of Healthcare companies in United States.
Owes vs Owns
0.73×Cumberland Pharmaceuticals Inc. owes $0.73 for every $1 it owns (moderate), higher than 73% of Healthcare companies in United States.
Dividend yield
NoneCumberland Pharmaceuticals Inc. does not currently pay a dividend.
Revenue growth
+18%Revenue rose 18% in the year to Dec 2025, and grew 2% a year on average over 3 years.
Profit growth
LossCumberland Pharmaceuticals Inc. made a loss in each of the last two years.
Profit margin
-6.4%Cumberland Pharmaceuticals Inc. lost $6 for every $100 of revenue.
Interest cover
Not coveredCumberland Pharmaceuticals Inc.'s operating profit did not cover its interest costs in the year to Dec 2025.
Cash vs debt
Net cashCumberland Pharmaceuticals Inc. held $1 M more cash than debt (net cash) at Dec 2025.
Questions
How is P/B calculated on PositoAI?
P/B is market cap divided by net worth from the latest balance sheet. For Cumberland Pharmaceuticals Inc.: $127 M ÷ $17 M (30 Jun 2026) = 7.3.
What is Cumberland Pharmaceuticals Inc.'s return on equity?
Cumberland Pharmaceuticals Inc. lost 14.4% of its shareholders' money over the last year, higher than 68% of Healthcare companies in United States.
How much does Cumberland Pharmaceuticals Inc. owe compared with what it owns?
Cumberland Pharmaceuticals Inc. owes $0.73 for every $1 it owns (moderate), higher than 73% of Healthcare companies in United States.
Does Cumberland Pharmaceuticals Inc. pay a dividend?
No. Cumberland Pharmaceuticals Inc. does not currently pay a dividend.
Is Cumberland Pharmaceuticals Inc.'s revenue growing?
Revenue rose 18% in the year to Dec 2025, and grew 2% a year on average over 3 years.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.